EGFR and non-small cell lung carcinoma: The phrase “SCLC transformation” is increasingly being used in clinical literature, especially for patients diagnosed with EGFR mutation-positive NSCLC after receiving EGFR tyrosine kinase inhibitor (TKI) therapy [15,16].